業績

  • トップ
  •  › 
  • 研究内容紹介
  •  › 
  • 業績

2017

Ohyashiki JH, Umezu T, Ohyashiki K. Extracellular vesicle-mediated cell-cell communication in haematologic neoplasms. Philos Trans R Soc Lond B Biol Sci. 2017, in press. [PubMed]
Umezu T, Imanishi S, Azuma K, Kobayashi C, Yoshizawa S, Ohyashiki K, Ohyashiki JH. Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis. Blood Advances. 2017, in press. [PubMed]
Asano M, Umezu T, Katagiri S, Kobayashi C, Tauchi T, Gotoh M, Ando K, Okabe S, Ohyashiki JH, Ohyashiki K. Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors. Int J Hematol. 2017, 105(4):419-22. [PubMed]

2016

Ohyashiki JH, Umezu T, Ohyashiki K. Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia. Curr Opin Hematol. 2016, 23(3):268-73. [PubMed]
Ohyashiki K, Umezu T, Katagiri S, Kobayashi C, Azuma K, Tauchi T, Okabe S, Fukuoka Y, Ohyashiki JH. Downregulation of plasma miR-215 in chronic myeloid leukemia patients with successful discontinuation of imatinib. Int J Mol Sci. 2016, 17(4):E570. [PubMed]

2015

Imanishi S, Takahashi R, Ohsuga M, Ohyashiki K, Ohyashiki JH. Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro. Ann Hematol. 2015, 94(9):1601-2. [PubMed]
Katagiri S, Tauchi T, Umezu T, Saito Y, Suguro T, Asano M, Yoshizawa S, Kitahara T, Akahane D, Tanaka Y, Fujimoto H, Okabe S, Gotoh M, Ito Y, Ohyashiki JH, Ohyashiki K. Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib. Rinsho Ketsueki. 2015, 56(2):216-9. [PubMed]

2014

Mizoguchi I, Yoshimoto T, Katagiri S, Furusawa J, Chiba Y, Mizuguchi J, Tauchi T, Ohyashiki JH, Ohyashiki K. Immunologic control of chronic myeloid leukemia leading to treatment-free remission. J Hematol Transfus. 2014, 2(3):1024.
Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014, 124(25):3748-3757. [PubMed]
Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T, Ohyashiki K. Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely. Drug Des Devel Ther. 2014, 8:1151-9. [PubMed]
Yoshimoto T, Mizoguchi I, Katagiri S, Tauchi T, Furusawa J, Chiba Y, Mizuguchi J, Ohyashiki JH, Ohyashiki K. Immunosurveillance Predictive markers to identify patients who can stop imatinib without relapse. Oncoimmunology. 2014, 3:e28861. [PubMed]
Imanishi S, Umezu T, Ohtsuki K, Kobayashi C, Ohyashiki K, Ohyashiki JH. Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines. Biochem Pharmacol. 2014, 89(3):361-9: [PubMed]
Ohyashiki K, Tadokoro K, Yamaguchi T, Katagiri S, Umezu T, Ohtsuki K, Tauchi T, Yamamoto Y, Ohyashiki JH. Detection of BIM (BCL2L11) polymorphic variants in Japanese chronic myeloid leukemia by Q-Invader assay and their clinical significance. J Hematol Transfus. 2014, 2(3): 1032.

2013

Tadokoro H, Umezu T, Ohyashiki K, Hirano T, and Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J. Biol. Chem. 2013, 288(48):34343-51. [PubMed]
Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y, Inokuchi K, Ohyashiki JH, Ohyashiki K. Sustained up-regulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci. 2013 104(9):1146-53. [PubMed]
Soeda S, Ohyashiki JH, Ohtsuki K, Umezu T, Setoguchi Y, Ohyashiki K. Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease. Int J Mol Med. 2013, 31(3):533-9. [PubMed]
Katagiri S, Umezu T, Ohyashiki JH, OHyashiki K. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukemia patients. Br J Haematol. 2013, 160(2):269-71. [PubMed]
Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene. 2013, 32(22):2747-55. [PubMed]

2012

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. BMC Med Genet. 2012, 13:6.
Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iisa S, Ohyashiki K. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012, 2(1):e53.
Ohyashiki M, Ohyashiki JH, Hirota A, Kobayashi C, Ohyashiki K. Age-related decrease of miRNA-92a levels in human CD8+ T-cells correlates with a reduction of naïve T lymphocytes. Immun Ageing. 2011, 8(1):11.
Ohyashiki K, Katagiri S, Tauchi T, Ohyashiki JH, Maeda Y, Matsumura I, Kyo T. Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol. 2012, 157(2):254-6.
Xu M, Takanashi M, Oikawa K, Nishi H, Isaka K, Yoshimoto T, Ohyashiki JH, Kuroda M. Identification of a novel role of Septin 10 in paclitaxel-resistance in cancers through a functional genomics screen. Cancer Sci. 2012, 103(4):821-7.
Kume K, Kikukawa M, Hanyu H, Takata Y, Umahara T, Sakurai H, Kanetaka H, Ohyashiki K, Ohyashiki JH, Iwamoto T. Telomere length shortening in patients with dementia with Lewy bodies. Eur J Neurol. 2012, 19(6):905-10.
Takata Y, Kikukawa M, Hanyu H, Koyama S, Shimizu S, Umahara T, Sakurai H, Iwamoto T, Ohyashiki K, Ohyashiki JH. An association between ApoE 4/4 phenotype and telomere erosion in Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2012, 67(4):330-5.
Nagano R, Akanuma H, Xian-Yang Qin, Imanishi S, Toyoshiba H, Yoshinaga J, Ohsako S, Sone H. Multi-parametric plofiling network based on gene expression and phenotype data: a novel approach to developmental neurotoxicity testing. Int J Mol Sci.2012, 13(1):187-207.
He X, Imanishi S, Sone H, Nagano R, Qin XY, Yoshinaga J, Akanuma H, Yamane J, Fujibuchi W, Ohsako S. Effects of methylmercury exposure on neuronal differentiation of mouse and human embryonic stem cells. Toxicol Lett. 2012, 212(1):1-10.
Akanuma H, Qin XY, Nagano R, Win-Shwe TT, Imanishi S, Zaha H, Yoshinaga J, Fukuda T, Ohsako S, Sone H. Identification of Stage-Specific Gene Expression Signatures in Response to Retinoic Acid during the Neural Differentiation of Mouse Embryonic Stem Cells. Front Genet. 2012, 3:141.

2011

Umezu T, Ohyashiki K, Ohyashiki JH. Detection method for quantifying global DNA methylation by fluorescence correlation spectroscopy. Analytical Biochemistry. 2011, 415(2):145-50.
Ohyashiki K, Umezu T, Yoshizawa S, Ito Y, Ohyashiki M, Kawashima H, Tanaka M, Kuroda M, Ohyashiki JH.Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS One. 2011, 6(2):e16408.
Aoki N, Tamura M, Ohyashiki JH, Sugaya M, Hisatomi H. Poloxamer 188 enhances apoptosis in a human leukemia cell line. Mol Med Rep. 2010, 3(4):669-72.
Ohyashiki K, Kodama A, Ohyashiki JH. Cytogenetics in myelodysplastic syndromes. Methods Mol Biol. 2011;730:79-88.
Imanishi S, Okura M, Zaha H, Yamamoto T, Akanuma H, Nagano R, Shiraishi H, Fujimaki H, Sone H. Prenatal exposure to permethrin influences vascular development of fetal brain and adult behavior in mice offspring. Environ Toxicol. 2011 Aug 24. doi: 10.1002/tox.20758. [Epub ahead of print]

2010

Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kuroda M, Ohyashiki K. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes. 2010, 3:347.
Yoshizawa S, Kitahara T, Zhang Y, Akahane D, Gotoh M, Ohyashiki K, Ohyashiki M, Ohyashiki JH. Determination of donor-derived killer immunoglobulin-like receptor (KIR) by sequential genotyping in hematopoietic stem cell-transplanted patients. Hematology. 2010, 15(6):397-405.
Ando K, Tanaka Y, Hashimoto Y, Ohyashiki JH, Sugimori N, Nakao S, Ohyashiki K. PNH-phenotype cells in patients with idiopathic cytopenia of undetermined significance (ICUS) with megakaryocytic hypoplasia and thrombocytopenia. Br J Haematol. 2010, 150(6):705-7.
Zhang Y, Ohyashiki JH, Shimizu N, Ohyashiki K. Aberrant expression of NK cell receptors in Epstein-Barr virus-positive gammadelta T-cell lymphoproliferative disorders. Hematology. 2010, 15(1):43-7.
Ando K, Kodama A, Iwabuchi T, Ohyashiki JH, Ohyashiki K. Idiopathic neutropenia with fewer than 5% dysplasia may be a distinct entity of idiopathic cytopenia of undetermined significance. Ann Hematol. 2010 Jul;89(7):733-5.
Ohtsuki K, Kasahara K, Shirahige K, Kokubo T. Genome-wide localization analysis of a complete set of Tafs reveals a specific effect of the taf1 mutation on Taf2 occupancy and provides indirect evidence for different TFIID conformations at different promoters. Nucleic Acid Research, 2010, 38(6):1805-20.
Mohri Y, Umezu T, Hidema S, Tomisawa H, Akamatsu A, Kato S, Nawa A, Nishimori K. Reduced fertility with impairment of early-stage embryos observed in mice lacking Lgr4 in epithelial tissues. Fertil Steril. 2010, 94(7):2878-81.
Umezu T, Yamanouchi H, Iida Y, Miura M, Tomooka Y. Follistatin-like-1, a diffusible mesenchymal factor determines the fate of epithelium. Proc Natl Acad Sci U S A. 2010, 107(10):4601-6.
Yamanouchi H, Umezu T, Tomooka Y. Reconstruction of oviduct and demonstration of epithelial fate determination in mice. Biol Reprod. 2010, 82(3):528-33.

2009

Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, Kuroda M. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One. 2009, 4(5):e5532
Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T and Ohyashiki K. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Cancer Letters. 2009, 284(1):62-70. 
Ohyashiki JH, Hisatomi H, Shimizu S, Sugaya M and Ohyashiki K. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis. Japn J Clin Oncol. 2009, 39(8):509-13
Okabe S, Tauchi T, Ohyashiki JH and Ohyashiki k. Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells. Biochem Biophys Res Commun. 2009, 380(4):775-9.
Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T Ohyahsiki K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Science. 2009, 100(5):970-7.